Sulfonamide inhibition studies of the beta-carbonic anhydrase from the newly discovered bacterium Enterobacter sp B13


EMİNOĞLU A., VULLO D., Asik A., Colak D. N. , ÇANAKÇI S. , BELDÜZ A. O. , ...More

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol.26, no.7, pp.1821-1826, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 7
  • Publication Date: 2016
  • Doi Number: 10.1016/j.bmcl.2016.02.032
  • Title of Journal : BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
  • Page Numbers: pp.1821-1826

Abstract

The genome of the newly identified bacterium Enterobacter sp. B13 encodes for a beta-class carbonic anhydrases (CAs, EC 4.2.1.1), EspCA. This enzyme was recently cloned, and characterized kinetically by this group (J. Enzyme Inhib. Med. Chem. 2016, 31). Here we report an inhibition study with sulfonamides and sulfamates of this enzyme. The best EspCA inhibitors were some sulfanylated sulfonamides with elongated molecules, metanilamide, 4-aminoalkyl-benzenesulfonamides, acetazolamide, and deacetylated methazolamide (K(I)s in the range of 58.7-96.5 nM). Clinically used agents such as methazolamide, ethoxzolamide, dorzolamide, brinzolamide, benzolamide, zonisamide, sulthiame, sulpiride, topiramate and valdecoxib were slightly less effective inhibitors (K(I)s in the range of 103-138 nM). Saccharin, celecoxib, dichlorophenamide and many simple benzenesulfonamides were even less effective as EspCA inhibitors, with K(I)s in the range of 384-938 nM. Identification of effective inhibitors of this bacterial enzyme may lead to pharmacological tools useful for understanding the physiological role(s) of the beta-class CAs in bacterial pathogenicity/virulence. (C) 2016 Elsevier Ltd. All rights reserved.